184 related articles for article (PubMed ID: 19705496)
21. Aggressive variant of splenic marginal zone lymphoma characterized using a cancer panel test and treated with rituximab-containing chemotherapy: A case report.
Ishiguro K; Sasaki Y; Takagi Y; Niinuma T; Suzuki H; Tokino T; Hayashi T; Takahashi T; Igarashi T; Matsuno Y
Medicine (Baltimore); 2020 Aug; 99(35):e21938. PubMed ID: 32871937
[TBL] [Abstract][Full Text] [Related]
22. Deoxycoformycin (pentostatin) in the treatment of splenic marginal zone lymphoma (SMZL) with or without villous lymphocytes.
Iannitto E; Minardi V; Calvaruso G; Ammatuna E; Florena AM; Mulè A; Tripodo C; Quintini G; Abbadessa V
Eur J Haematol; 2005 Aug; 75(2):130-5. PubMed ID: 16000129
[TBL] [Abstract][Full Text] [Related]
23. Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone.
Tsimberidou AM; Catovsky D; Schlette E; O'Brien S; Wierda WG; Kantarjian H; Garcia-Manero G; Wen S; Do KA; Lerner S; Keating MJ
Cancer; 2006 Jul; 107(1):125-35. PubMed ID: 16700034
[TBL] [Abstract][Full Text] [Related]
24. Outcomes in splenic marginal zone lymphoma: analysis of 107 patients treated in British Columbia.
Xing KH; Kahlon A; Skinnider BF; Connors JM; Gascoyne RD; Sehn LH; Savage KJ; Slack GW; Shenkier TN; Klasa R; Gerrie AS; Villa D
Br J Haematol; 2015 May; 169(4):520-7. PubMed ID: 25854936
[TBL] [Abstract][Full Text] [Related]
25. Risk adapted approach: How to treat splenic marginal zone lymphoma in resource-poor settings? - The real-life experience of a Brazilian cancer treatment center.
de Pádua Covas Lage LA; Dos Santos FFC; Levy D; Moreira FR; Couto SCF; Culler HF; de Oliveira Costa R; Rocha V; Pereira J
BMC Cancer; 2020 Aug; 20(1):717. PubMed ID: 32746790
[TBL] [Abstract][Full Text] [Related]
26. Peri-operative complications and hematologic improvement after first-line splenectomy for splenic marginal zone lymphoma.
Pata G; Damiani E; Bartoli M; Solari S; Anastasia A; Pagani C; Tucci A; Ragni F
Leuk Lymphoma; 2016; 57(6):1467-70. PubMed ID: 26373930
[No Abstract] [Full Text] [Related]
27. Rituximab monotherapy for splenic marginal zone lymphoma with villous lymphocytes: report on long-term disease control for two patients with recurrence after splenectomy.
Debiasi M; Hehnemann M; Garicochea B
Sao Paulo Med J; 2010 Dec; 128(6):375-7. PubMed ID: 21308163
[TBL] [Abstract][Full Text] [Related]
28. Splenic marginal zone lymphoma: from genetics to management.
Arcaini L; Rossi D; Paulli M
Blood; 2016 Apr; 127(17):2072-81. PubMed ID: 26989207
[TBL] [Abstract][Full Text] [Related]
29. No evidence of splenic disease in patients with splenic marginal zone lymphoma undergoing splenectomy for autoimmune hemolytic anemia after monotherapy with rituximab.
Kalpadakis C; Pangalis GA; Sachanas S; Rontogianni D; Korkolopoulou P; Milionis V; Vassilakopoulos TP; Papadaki HA; Angelopoulou MK
Leuk Lymphoma; 2016 Nov; 57(11):2705-8. PubMed ID: 27082039
[No Abstract] [Full Text] [Related]
30. Significant efficacy of 2-CdA with or without rituximab in the treatment of splenic marginal zone lymphoma (SMZL).
Cervetti G; Galimberti S; Sordi E; Buda G; Orciuolo E; Cecconi N; Petrini M
Ann Oncol; 2010 Apr; 21(4):851-854. PubMed ID: 19825880
[TBL] [Abstract][Full Text] [Related]
31. Time Trend Analysis of Splenectomy for Splenic Marginal Zone Lymphoma: Declining Surgery, Promising Survival.
Yang Z; Liu L; Leng K; Shi G
Ann Surg Oncol; 2023 Nov; 30(12):7206-7216. PubMed ID: 37516724
[TBL] [Abstract][Full Text] [Related]
32. Splenectomy in Lymphoproliferative Disorders: A Single Eastern European Center Experience.
Onisâi M; Vlădăreanu AM; Nica A; Spînu A; Găman M; Bumbea H; Voican I; Iordan I; Alexandru A; Zdrenghea M; Gheorghita D; Grădinaru S
Medicina (Kaunas); 2019 Dec; 56(1):. PubMed ID: 31892196
[No Abstract] [Full Text] [Related]
33. Superior outcome for splenectomised patients in a population-based study of splenic marginal zone lymphoma in Sweden.
Sima A; Hollander P; Baecklund E; Smedby KE; Enblad G; Amini RM
Br J Haematol; 2021 Aug; 194(3):568-579. PubMed ID: 34109612
[TBL] [Abstract][Full Text] [Related]
34. [Splenic marginal zone lymphoma complicated by cold agglutinin disease].
Ochi K; Yokoyama K; Ohno N; Ota Y; Tojo A
Rinsho Ketsueki; 2017; 58(2):132-137. PubMed ID: 28321090
[TBL] [Abstract][Full Text] [Related]
35. How to treat splenic marginal zone lymphoma (SMZL) in patients unfit for surgery or more aggressive therapies: experience in 30 cases.
Cervetti G; Ghio F; Cecconi N; Morganti R; Galimberti S; Petrini M
J Chemother; 2017 Apr; 29(2):126-129. PubMed ID: 27454143
[TBL] [Abstract][Full Text] [Related]
36. Should rituximab replace splenectomy in the management of splenic marginal zone lymphoma?
Kalpadakis C; Pangalis GA; Angelopoulou MK; Sachanas S; Vassilakopoulos TP
Best Pract Res Clin Haematol; 2018 Mar; 31(1):65-72. PubMed ID: 29452668
[TBL] [Abstract][Full Text] [Related]
37. Remission of Cutaneous Involvement in Splenic Marginal Zone Lymphoma after Splenectomy.
Mai S; Natsuga K; Shiratori S; Takahashi Y; Shimizu H
Acta Derm Venereol; 2018 Aug; 98(8):801-802. PubMed ID: 29856467
[No Abstract] [Full Text] [Related]
38. First-line treatment with bendamustine and rituximab, in patients with intermediate-/high-risk splenic marginal zone lymphomas.
Castelli R; Bergamaschini L; Deliliers GL
Med Oncol; 2017 Dec; 35(2):15. PubMed ID: 29288421
[TBL] [Abstract][Full Text] [Related]
39. Lupus anticoagulant and thrombosis in splenic marginal zone lymphoma.
Gebhart J; Lechner K; Skrabs C; Sliwa T; Müldür E; Ludwig H; Nösslinger T; Vanura K; Stamatopoulos K; Simonitsch-Klupp I; Chott A; Quehenberger P; Mitterbauer-Hohendanner G; Pabinger I; Jäger U; Geissler K
Thromb Res; 2014 Nov; 134(5):980-4. PubMed ID: 25201005
[TBL] [Abstract][Full Text] [Related]
40. Splenic marginal zone lymphoma: a case report and literature review.
Zhang S; Xuan Z; Zhang L; Lu J; Song P; Zheng S
World J Surg Oncol; 2020 Oct; 18(1):259. PubMed ID: 33004051
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]